About: Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study
Creator	Li, Lan-Juan Qiu, Yun-Qing Sheng, Ji-Fang Yu, Liang Zhang, Xiao-Li Zheng, Lin Jin, Xi Yang, Yi-Da Cai, Huan Gu, Jue-Qing Hao, Shao-Rui Hu, Jian-Hua Jia, Hong-Yu Jin, Ci-Liang Lian, Jiang-Shan Lu, Ying-Feng Wang, Xiao-Yan Xiang, Dai-Rong Ye, Chan-Yuan Yu, Guo-Dong Yu, Xiao-Peng Zhang, Shan-Yan Zhang, Yi-Min Liang, Ting-Bo Ye, Cheng-Yin
Source	Medline; PMC
abstract	INTRODUCTION: Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. METHODS: Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control group. Reverse transcription polymerase chain reaction was used to confirm severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and patients symptomatic with SARS-CoV-2 infection were defined as patients with COVID-19. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected and compared. RESULTS: Of 788 patients with COVID-19, 222 (28.2%) patients had elevated liver enzyme levels (median [interquartile range {IQR}] age, 47.0 [35.0–55.0] years; 40.5% women). Being male, overweight, and smoking increased the risk of liver enzyme level elevation. The liver enzyme level elevation group had lesser pharyngalgia and more diarrhea than the control group. The median time from illness onset to admission was 3 days for liver enzyme level elevation groups (IQR, 2–6), whereas the median hospitalization time for 86 (38.7%) discharged patients was 13 days (IQR, 11–16). No differences in disease severity and clinical outcomes were noted between the groups. DISCUSSION: We found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission, which could partially be related to SARS-CoV-2 infection. Male patients had a higher risk of liver enzyme level elevation. With early medical intervention, liver enzyme level elevation did not worsen the outcomes of patients with COVID-19.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.14309/ajg.0000000000000717
bibo:pmid	32483005
has license	no-cc
sha1sum (hex)	5990a318c13012b474303b722bcf6b49e950edba
schema:url	https://doi.org/10.14309/ajg.0000000000000717
resource representing a document's title	Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study
has PubMed Central identifier	PMC7288765
has PubMed identifier	32483005
schema:publication	Am J Gastroenterol
resource representing a document's body	covid:5990a318c13012b474303b722bcf6b49e950edba#body_text
is schema:about of	named entity 'Study' named entity 'Cross-Sectional Study' named entity 'COVID' named entity 'hemoglobin' named entity 'control group' named entity 'cholangiocytes' named entity 'febuxostat' named entity 'control group' named entity 'genomic analysis' named entity 'control group' named entity 'ACE2' named entity 'sex hormones' named entity 'procalcitonin' named entity 'infection' named entity 'China' named entity 'severe pneumonia' named entity 'Liver' named entity 'chronic diseases' named entity 'microvesicular steatosis' named entity 'ICU' named entity 'COVID' named entity 'cirrhosis of the liver' named entity 'elevated liver enzyme levels' named entity 'Zhejiang Province' named entity 'SARS-CoV-2 virus' named entity 'alcohol' named entity 'WHO' named entity 'liver enzyme elevation' named entity 'cross-sectional study' named entity 'liver enzyme elevation' named entity 'clinical symptoms' named entity 'SARS-CoV-2' named entity 'elevated liver enzyme levels' named entity 'septic shock' named entity 'COVID' named entity 'liver injury' named entity 'Liver enzyme' named entity 'Acute infection' named entity 'Zhejiang Province' named entity 'chronic liver disease' named entity 'liver damage' named entity 'control groups' named entity 'albumin' named entity 'COVID-19' named entity 'viral hepatitis' named entity 'pneumonia' named entity 'lopinavir/ritonavir' named entity 'liver injury' named entity 'supportive treatment' named entity 'ICU' named entity 'control group' named entity 'diarrhea' named entity 'SARS-CoV-2' named entity 'clinical features' named entity 'clinical characteristics' named entity 'blood urea nitrogen' named entity 'liver enzyme'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software